Development asset linked to Apotex Pty in public FDA and regional records. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
pharma
Apotex Pty
Apotex Pty Ltd
Apotex Pty drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
AU HQ
TGA registrant Type
Company details
- Status
- Public
- HQ
- AU
- Programs
- 0
- Drugs
- 11
- Patents
- 0
Apotex Pty pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Apotex Pty drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
Development asset linked to Apotex Pty in public FDA and regional records. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor antagonist
-
fentanyl
Nervous system (N02)US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Apotex Pty in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Apotex Pty in public FDA and regional records.
-
Development asset linked to Apotex Pty in public FDA and regional records.
-
zoledronic acid
Musculo-skeletal system (M05)US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.
- Target
- Farnesyl pyrophosphate synthase
- Mechanism
- Farnesyl diphosphate synthase inhibitor